May 15, 2025
LA JOLLA—Horacio Valeiras, CEO of Frontier Global Partners, has been newly appointed to the Salk Institute’s Consejo de Administración. He will work alongside business and nonprofit leaders from around the world, all committed to supporting Salk’s innovative, high-quality scientific research.
Valeiras started as a chemical engineer, which laid a scientific foundation that informed his MBA studies and 40-year career in finance. Originally from Buenos Aires, Argentina, Valeiras traveled from New York to London for work before settling in La Jolla more than 20 years ago.
“Horacio’s keen understanding of global technology markets makes him a tremendous asset to all of us at Salk,” says Salk President Gerald Joyce. “He truly understands our mission, priorities, and needs, and we look forward to benefitting from his expertise in the coming years.”
Valeiras earned his bachelor’s degree in chemical engineering at Virginia Tech and his master’s degree at MIT. While in Boston, he began taking business classes and quickly realized the discipline and analytical skills he developed as an engineer were also powerful business skills. This inspired his postgraduation pivot from chemicals research at Chevron to earning his MBA at UC Berkeley, which allowed him to take on investment roles at Anderson & Sherrerd and later act as managing director of Morgan Stanley Investment Management. Valeiras went on to serve as chief investment officer at Allianz Global Investors in 2002, and he later founded HAV Capital LLC, which merged into Frontier Global Partners, where he’s currently CEO.
“Science has always been the foundation of my practice, so joining the Board of Trustees at a prestigious basic research institute like Salk is truly meaningful to me,” says Valeiras. “Supporting the work of Salk’s world-renowned scientists will be an enriching and exciting endeavor in the years to come.”
Oficina de Comunicaciones
Tel.: (858) 453-4100
press@salk.edu
El Instituto Salk es un centro de investigación independiente y sin fines de lucro fundado en 1960 por Jonas Salk, creador de la primera vacuna segura y eficaz contra la poliomielitis. La misión del Instituto es impulsar una investigación fundamental, colaborativa y audaz que aborde los retos más acuciantes de la sociedad, entre ellos el cáncer, la enfermedad de Alzheimer y la vulnerabilidad agrícola. Esta ciencia fundamental sustenta todos los esfuerzos traslacionales, generando conocimientos que permiten el desarrollo de nuevos medicamentos e innovaciones en todo el mundo.
